^
Association details:
| Biomarker: | NRG1 overexpression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
Published date:
08/12/2021
Excerpt:
To characterize expression of neuregulin-1 (NRG1), an HER3 ligand, in HER2-positive breast cancer and its relation with the efficacy of trastuzumab with or without pertuzumab. In the NeoSphere trial, the magnitude of the difference of pathologic complete response rates favoring the pertuzumab arm was higher in the NRG1-high group. In patients with HER2-positive breast cancer, high expression of NRG1 was associated to poor response to trastuzumab, but not in combination with pertuzumab.
DOI:
10.1158/1078-0432.CCR-20-2915
Trial ID:
